Related Experiment Videos
Good news for billions of children who will receive IPV
1Kid Risk, Orlando, FL 32827, USA; UCF College of Medicine, Orlando, FL 32827, USA.
The Lancet. Infectious Diseases
|August 21, 2015
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Collateral damage from violent incidents: human costs of polio immunization.
Bulletin of the World Health Organization·2025
Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV).
Pathogens (Basel, Switzerland)·2024
Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.
Pathogens (Basel, Switzerland)·2024
Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs).
Expert review of vaccines·2024
When the fungus is susceptible, but the patient is not: reading antifungal susceptibility from bench to bedside.
The Lancet. Infectious diseases·2026
Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study.
The Lancet. Infectious diseases·2026
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6-17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial.
The Lancet. Infectious diseases·2026